2 terminated, 1 completed. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Terminated 2, Completed 1 |
Follow IDX 899: new trials by email Literature Review of IDX 899 trials Research Report on IDX 899
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dose-finding Study of GSK2248761 in Antiretroviral Therapy-Naive Subjects (SIGNET) GSK2248761 100 mg once daily, GSK2248761 200 mg once daily, Efavirenz 600 mg once daily - Infection, Human Immunodeficiency Virus | Phase 2 | Terminated | ViiV Healthcare | 23 | 2010-11-18 | 2017-11-17 |
| Dose-finding Study of GSK2248761 in Antiretroviral Therapy-experienced Subjects With NNRTI-resistant HIV Infection GSK2248761 100 mg once daily, GSK2248761 200 mg once daily, Etravirine - Infection, Human Immunodeficiency Virus | Phase 2 | Terminated | ViiV Healthcare | 30 | 2010-10-05 | 2017-11-17 |
| Safety and Tolerability Study to Evaluate Lower Dose of GSK2248761 in Antiretroviral Treatment-Naive HIV-1 Infected Adults. GSK2248761, Lopinavir/ritonavir, HAART - Infection, Human Immunodeficiency Virus | Phase 2 | Completed | ViiV Healthcare | 8 | 2009-10-20 | 2018-11-29 |
Acquired Immunodeficiency Syndrome (3) · HIV Infections (3) · Infections (3) · Immunologic Deficiency Syndromes (1) · Retroviridae Infections (1) · Sexually Transmitted Diseases (1)
ViiV Healthcare (3)
Argentina (1) · Belgium (1) · Canada (1) · France (1) · Germany (1) · Italy (1) · Romania (1) · Spain (1) · United States (1)